ClinicalTrials.gg
CompletedNCT05397223Updated Mar 12, 2026

A Study of Modified mRNA Vaccines in Healthy Adults

A Phase 1 interventional study of mRNA-1273 and mRNA-1010 in SARS-CoV-2, Seasonal Influenza and Respiratory Syncytial Virus, sponsored by ModernaTX, Inc.. Completed at 8 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-12.

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
308
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing 2019-nCoV Vaccine mRNA-1273 in Coronavirus Infections — 2 open to participants now, 3 under way, none of them phase 3. 2019-nCoV Vaccine mRNA-1273 · Coronavirus Infections.

Enrollment
9th of 11
308 · median 1,144
Started
2022
the only one that year
Phase 1
2 of 11
none open now
Registered
8th of 11
by date
Lead sponsor
11 of 11
ModernaTX, Inc.

Among the 11 studies testing 2019-nCoV Vaccine mRNA-1273 in Coronavirus Infections, this one is the 9th largest by enrollment, is the only one that started in 2022, is one of 2 in phase 1, and was the 8th registered.

Coronavirus Infections

1,112 studies on the registry are indexed under Coronavirus Infections; 52 are open to participants now.

Browse Coronavirus Infections studies →

Open to participants now

2 of the 11 studies testing 2019-nCoV Vaccine mRNA-1273 in Coronavirus Infections are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About 2019-nCoV Vaccine mRNA-1273

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 40 Coronavirus Infections studies recruiting now, 24 (60%) set no upper age limit and 9 (23%) stop at 75 or younger; 13 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing 2019-nCoV Vaccine mRNA-1273 in Coronavirus Infections, or all of them as a file.
02

Study summary

The main goal of this study is to evaluate the safety, reactogenicity, and immunogenicity of study vaccines.

03

Conditions studied

  • SARS-CoV-2
  • Seasonal Influenza
  • Respiratory Syncytial Virus
  • Cytomegalovirus

Keywords

  • mRNA-1273
  • mRNA-1273 vaccine
  • SARS-CoV-2
  • SARS-CoV-2 Vaccine
  • Coronavirus
  • Virus Diseases
  • Messenger RNA
  • COVID-19
  • COVID-19 Vaccine
  • Moderna
  • Influenza vaccine
  • mRNA-1010
  • mRNA-1345
  • Respiratory syncytial virus
  • RSV Seropositive
  • Vaccines
  • mRNA-1647
  • Cytomegalovirus
  • CMV
  • Cytomegalovirus Vaccine
  • Cytomegalovirus Infections
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults 18 to 75 years of age at the time of consent (screening visit) who, in the opinion of the investigator, are in good health based on review of medical history and physical examination performed at screening. For mRNA-1647 study arms, adults 18 to \<50 years of age at the time of consent (screening visit) who, in the opinion of the investigator, are in good health based on review of medical history and physical examination performed at screening.
  • (BMI) of 18 kilograms (kg)/square meter (m\^2) to 35 kg/m\^2 (inclusive) at the screening visit.

Exclusion criteria

Exclusion Criteria:

  • Participant has had close contact to someone with confirmed SARS-CoV-2, respiratory syncytial virus (RSV), or influenza infection in the past 14 days prior to the screening visit.
  • Severe allergic reaction to any component of the FLUAD vaccine (active comparator), including egg protein, or after a previous dose of any influenza vaccine.
  • Participant has received systemic or immune-modifying drugs for >14 days in total within 6 months prior to screening (to include any systemic ) or is anticipating the need for immunosuppressive treatment at any time during participation in the study.
  • Participant plans to receive any licensed or authorized vaccine, including COVID-19 influenza vaccines, within 28 days before or after any study injection.
  • Participant has received a NH 2021 - 2022 or 2022-2023 seasonal influenza vaccine or any other influenza vaccine, or an experimental RSV or cytomegalovirus (CMV) vaccine, within 6 months prior to study Day 1, and/or has not completed a primary vaccination series for COVID-19.
  • Participant has received an authorized or approved COVID-19 vaccine within 4 months prior to Day 1, and/or has not completed a primary vaccination series for COVID-19.
  • Participant had a laboratory-confirmed infection with influenza or RSV within 6 months prior to Day 1, or SARS-CoV-2 within 4 months of Day 1. SARS-CoV-2 infection confirmed with self-administered, authorized or approved rapid antigen test is acceptable.
  • Participant has donated ≥450 milliliters (mL) of blood products within 28 days prior to the screening visit or plans to donate blood products during the study.
  • Participated in an interventional clinical study within 28 days prior to the screening visit based on the medical history interview or plans to do so while participating in this study until 12 months after their last study vaccination.

Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
308 participants (actual)

Study arms

  • Experimental
    Part 1: mRNA-1345

    Participants will receive single intramuscular (IM) injection of mRNA-1345 on Day 1.

    Biological: mRNA-1345

  • Experimental
    Part 1: mRNA-1647 2-Dose

    Participants will receive single IM injection of mRNA-1647 on Days 1 and 57.

    Biological: mRNA-1647

  • Experimental
    Part 1: mRNA-1647 3-Dose

    Participants will receive single IM injection of mRNA-1647 on Days 1, 57, and 169.

    Biological: mRNA-1647

  • Experimental
    Part 2: mRNA-1273

    Participants will receive single IM injection of mRNA-1273 on Day 1

    Biological: mRNA-1273

  • Experimental
    Part 2: mRNA-1010

    Participants will receive single IM injection of mRNA-1010 on Day 1.

    Biological: mRNA-1010

  • Active comparator
    Part 2: FLUAD®

    Participants will receive single IM injection of FLUAD® on Day 1.

    Biological: FLUAD®

Interventions

  • BiologicalmRNA-1273

    Sterile liquid for injection

  • BiologicalmRNA-1010

    Sterile liquid for injection

  • BiologicalmRNA-1345

    Sterile liquid for injection

  • BiologicalFLUAD®

    adjuvanted (MF59), inactivated, quadrivalent seasonal influenza vaccine

  • BiologicalmRNA-1647

    Sterile lyophilized product

06

What researchers measure

Primary outcomes

  1. Number of Participants With Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)

    Time frame: Up to Day 176 (7 days follow-up post-vaccination)

  2. Number of Participants With Unsolicited Adverse Events (AEs)

    Time frame: Up to Day 197 (28 days follow-up post-vaccination)

  3. Number of Participants With Serious AEs (SAEs), AEs of Special Interest (AESIs), and AEs Leading to Study Withdrawal or Discontinuation of Study Vaccination

    Time frame: Day 1 through end of study (EOS) (up to Day 1249)

  4. Number of Participants with Medically Attended Adverse Events (MAAEs)

    Time frame: Day 1 through Day 361

Secondary outcomes

  1. Geometric Mean Titer (GMT) of Serum Neutralizing Antibody Response for mRNA-1010 (and Licensed Influenza Vaccine Comparator), mRNA-1273, and mRNA-1345

    Time frame: Days 1 (Baseline), 29, 85, and 197

  2. Geometric Mean Fold-Rise (GMFR) of Serum Neutralizing Antibody Response for mRNA-1010 (and Licensed Influenza Vaccine Comparator), mRNA-1273, and mRNA-1345

    Time frame: Days 1 (Baseline), 29, 85, and 197

  3. Percentage of Participants With Seroresponse for mRNA-1010 (and Licensed Influenza Vaccine Comparator), mRNA-1273, mRNA-1345, and mRNA-1647

    Time frame: Days 1 (Baseline), 29, 85, and 197

07

Study locations

8 sites
  • CenExel
    Hollywood, Florida 33024, United States
  • Meridian Clinical Research
    Savannah, Georgia 31406, United States
  • Meridian Clinical Research
    Sioux City, Iowa 51106, United States
  • Johnson County Clinical Trials
    Lenexa, Kansas 66219, United States
  • Meridian Clinical Research
    Lincoln, Nebraska 68510, United States
  • Benchmark Research
    Austin, Texas 78705, United States
  • Tekton Research, Inc
    Austin, Texas 78745, United States
  • DM Clinical Research- Texas Center for Drug Development
    Houston, Texas 77081, United States
08

References and documents

Publications

  • Henry C, Makrinos D, Liu R, Cavallaro M, Fenderson B, Sun Y, Chang X, Astley E, Girard B, Yu WH, Oostendorp J, DiPiazza A, Paris R. An mRNA influenza vaccine induces immunity comparable to an adjuvanted vaccine in a randomized trial. NPJ Vaccines. 2026 Jan 14;11(1):50. doi: 10.1038/s41541-026-01370-7. PubMed 41535296 ↗
  • Kaplonek P, Vargas R, Lee JS, Bertera H, Astley E, Girard B, Oostendorp J, Henry C, Paris R, Yu WH, Alter G. mRNA-1010 influenza vaccine elicits distinct and enhanced humoral immunity compared to adjuvanted inactivated vaccines. NPJ Vaccines. 2025 Dec 15;11(1):19. doi: 10.1038/s41541-025-01340-5. PubMed 41398408 ↗
  • Fierro C, Sanchez-Crespo N, Makrinos D, Zhang W, Sun Y, Rohilla P, Girard B, Adeniji A, DiPiazza A, Paris R. Shared clinical and immunologic features of mRNA vaccines: preliminary results from a comparative clinical study. Front Immunol. 2025 Apr 10;16:1501275. doi: 10.3389/fimmu.2025.1501275. eCollection 2025. PubMed 40276503 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Feb 2026, 45 months.

Of 35 industry-sponsored phase 1 interventional studies under Coronavirus Infections, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 15. This study's 45 months is above that.

Counting every sponsor, half of 61 studies reached it within 10 months; a quarter within 3 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2022
First posted
May 31, 2022
StartActual
May 24, 2022
Primary completionActual
Feb 27, 2026
CompletionActual
Feb 27, 2026
Last update
Mar 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05397223
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
May 31, 2022
Start date
May 24, 2022
Primary completion
Feb 27, 2026
Completion
Feb 27, 2026
Last update
Mar 12, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: 2019-nCoV Vaccine mRNA-1273 · mRNA-1010 influenza vaccine · mRNA-1345 respiratory syncytial virus vaccine · mRNA-1647 cytomegalovirus vaccine

Start the discussion